Testosterone Therapy Safe Despite Prostate Cancer
New studies find no increase in biochemical recurrence risk following radical prostatectomy or radiation therapy associated with testosterone replacement therapy.
Prostate Cancer
A Novel Method for Biomarker Discovery in Clinical Trials
A new study reveals a unique method of biomarker discovery that has the potential to be used to identify responder subpopulations in clinical trials.
Darolutamide Gets Priority Review for Non-Metastatic Castration-Resistant Prostate Cancer
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for darolutamide (Bayer and Orion), an investigational treatment for non-metastatic castration-resistant prostate cancer (nmCRPC).
Single-Dose Brachytherapy Effective for Prostate Cancer
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease
Study Reports Marijuana Use Among Patients With Cancer May Be Increasing While Opioid Use Stays Stable, but Questions Remain
The proportion of participants with cancer who used marijuana increased 118% from the period of 2005 to 2014.
Navigating Cancer Communication on Twitter
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Prostate Cancer ADT Found to Increase Depression Risk
Men who receive androgen deprivation therapy after radical prostatectomy have a nearly 2-fold increased risk of depression compared with those who receive no post-surgical treatment.
Wider Use of Basket Trials Could Hasten Development of Precision Therapies
Basket trials are those that test investigational therapies in patients who have different types of cancer but share a particular genomic aberration.
AR-V7 Positivity May Inform Treatment Decisions for mCRPC
Men with aggressive prostate cancer who test positive for AR-V7 in circulating tumors cells are unlikely to benefit from treatment with abiraterone or enzalutamide.
Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts.
Next post in General Oncology
